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Abstract We have employed an amino derivative of the
imidazoline ligand, efaroxan, to isolate imidazoline binding
proteins from solubilised extracts of rat brain, by affinity
chromatography. A number of proteins were specifically retained
on the affinity column and one of these was immunoreactive with
an antiserum raised against the ion conducting pore component
of the ATP-sensitive potassium channel. Patch clamp experi-
ments confirmed that, like its parent compound, amino-efaroxan
blocks ATP-sensitive potassium channels in human pancreatic L-
cells and can stimulate the insulin secretion from these cells. The
results reveal that a member of the ion conducting pore
component family is strongly associated with imidazoline binding
proteins in brain and in the endocrine pancreas.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Imidazoline binding sites are present in a range of tissues
and have emerged over recent years as candidates for a new
class of receptors having a unique pharmacology [1^5]. They
have been subclassi¢ed according to their ligand recognition
properties into two principal subtypes (I1 and I2 binding sites)
and these are found in many regions of the central nervous
system (CNS) [1^10] as well as in peripheral tissues such as the
adrenal medulla, liver, kidney, platelets and placenta [11^17].
In most cases, their presence has been demonstrated by ligand
binding although functional responses have also been de¢ned
in some tissues. Perhaps the best characterised of these is the
stimulation of insulin secretion by imidazolines such as efar-
oxan and phentolamine [18^22], a response ascribed to the
activation of an atypical subtype of the imidazoline binding
site, recently designated I3 [4] to di¡erentiate it from the I1
and I2 subtypes expressed elsewhere.
There is evidence that the I3-imidazoline binding site in
pancreatic L-cells may be associated with ATP-sensitive po-
tassium (KATP) channels since, when islets are treated with
imidazoline insulin, secretogogues KATP channels close [19^
26]. This results in membrane depolarisation, calcium in£ux
and insulin secretion (reviewed in [4,27,28]). Thus, binding of
ligands to the I3 site appears to regulate the opening of KATP
channels.
Recent work has revealed that KATP channels are multi-
meric proteins containing at least two di¡erent subunits, a
regulatory ATP binding cassette component, designated
SUR (which contains the binding site for sulphonylureas
and occurs in at least three di¡erent isoforms) and a ion
conducting pore component, Kir6.x (reviewed in [29^32]).
Two genes have been identi¢ed which encode members of
the Kir6.x family. One of these (Kir6.1) is expressed ubiquit-
ously [33] and the second, Kir6.2 (molecular weight approx-
imately 48 kDa), is more restricted in distribution, being lo-
calised principally in neuroendocrine cells [34]. It has not been
established whether an additional subunit is required to confer
sensitivity to imidazolines but there is strong evidence that the
imidazoline binding site does not reside on SUR. Thus, imi-
dazolines do not displace sulphonylurea binding in L-cells [35]
and more signi¢cantly, phentolamine has been reported to
induce closure of a truncated form of the pancreatic L-cell
channel, Kir6.2, expressed in the absence of SUR [26]. This
evidence has been interpreted to indicate that the binding site
for imidazolines may lie within the ion conducting subunit of
the channel, although this remains to be demonstrated di-
rectly.
In order to address this issue, we have used an a⁄nity
isolation approach to identify proteins that can interact with
the imidazoline efaroxan. Efaroxan binds with high a⁄nity to
I1-imidazoline binding sites [36] but is also an e¡ective insulin
secretagogue by virtue of its activity at I3 sites [4,28]. Thus, it
represents a useful ligand for identi¢cation of imidazoline
binding proteins. We have employed rat brain extracts as
the source of imidazoline binding sites since I sites, Kir6.2
and SUR1 are present in this tissue.
2. Materials and methods
2.1. A⁄nity chromatography
An efaroxan a⁄nity column was generated by coupling 5P-amino-
efaroxan (KU08C, synthesised as described in [37]) to Aminolink
(Pierce, USA), according to the manufacturer’s instructions. Mem-
branes were prepared by homogenising rat brains in 50 mM Tris
bu¡er, pH 7.4, supplemented with protease inhibitors (¢nal concen-
trations of phenylmethylsulphonyl £uoride 200 WM, aprotonin 10 Wg/
ml, leupeptin 1 WM, EDTA 1 mM)) (Sigma, UK). Following an initial
centrifugation step at 4000Ug for 10 min at 4‡C, the supernatant was
centrifuged at 40 000Ug for 20 min at 4‡C. The membrane pellet was
then solubilised in 50 mM Tris-HCl, pH 7.4, containing protease
inhibitors and a ¢nal concentration of 0.5% CHAPS (w/v) (Sigma,
UK). The suspension was then centrifuged at 40 000Ug and the super-
natant retained. A protein determination was performed using the
BCA protein assay kit (Pierce) and bovine serum albumin as a stand-
ard.
All bu¡ers for the a⁄nity chromatography contained 50 mM Tris-
HCl, pH 7.4, with protease inhibitors (as above) and 0.05% (w/v)
CHAPS and all procedures were performed at 4‡C. 50 mg of solubi-
lised brain protein was applied to the column. The column was then
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washed to remove non-speci¢cally bound proteins and the retained
proteins were eluted sequentially with the K2-adrenoceptor agonist
UK14304 (1 mM, donated by P¢zer, UK), the mixed adrenoceptor/
imidazoline ligand efaroxan (100 WM, synthesised by Dept. of Chem-
istry, Keele University) and ¢nally with 1 M KCl. All three fractions
were collected, dialysed, concentrated and analysed by SDS-PAGE
using a 10% (v/v) polyacrylamide gel. Pre-stained molecular weight
markers (10 Wl Gibco BRL) were run alongside the samples. Samples
were run in duplicate so that one gel could undergo silver staining for
protein detection, whilst the proteins on the second gel were trans-
ferred to a PVDF membrane. The membrane was incubated for 1 h at
room temperature in 2% (v/v) goat serum in Tris-bu¡ered saline sup-
plemented with 0.1% (v/v) Tween X-100 (TTBS) to block non-speci¢c
binding sites. It was then incubated with polyclonal anti-Kir6.2 anti-
sera (diluted 1:1000 in 1% (v/v) goat serum in TTBS), overnight at
4‡C. After several washes in TTBS, the membrane was incubated with
a secondary goat anti-rabbit antisera (diluted 1:30 000 in 1% (v/v)
goat serum in TTBS) for 1 h at room temperature. The membrane
was washed sequentially in TTBS and then TBS and the blot was
analysed by a colorimetric method (BCIP/NBT (Sigma)) according
to the manufacturers protocol.
2.2. Electrophysiology
All data were obtained from primary cultured human islet cells
using the inside-out recording con¢guration of the patch clamp tech-
nique. The patch pipette was ¢lled with a solution consisting of (in
mM) 140 NaCl, 4.7 KCl, 1.13 MgCl2, 2.5 CaCl2, 10 N-(2-hydroxy-
ethyl)piperazine-NP-(2-ethanesulphonic acid (HEPES), 2.5 glucose
(pH 7.4 with NaOH). Efaroxan was dissolved in water and KU08C
dissolved in dimethylsulphoxide (DMSO) to produce 100 mM stock
solutions which were serially diluted into working solutions contain-
ing (in mM) 0.001^0.1 efaroxan or KU08C, 140 KCl, 10 NaCl, 1.13
MgCl2, 10 HEPES, 2.5 glucose, 1 ethylenebis(oxyethylenenitrilo)tetra-
acetic acid (EGTA) (pH 7.2 with KOH). The maximum concentration
of DMSO was 6 1%, which has no e¡ect on KATP channels [38]. To
minimise the e¡ects of channel run down [39], inside-out patches were
continuously exposed to 0.5 mM ATP (K salt, Sigma, UK) and ATP
was removed only during those periods when the patch was exposed,
for a minimum of 20 s, to control solutions or various concentrations
of efaroxan or KU08C.
Data were recorded at 0 mV voltage clamp using a List L/M EPC-7
patch clamp ampli¢er (List Electronic, Darmstadt, Germany). All
experiments were carried out at room temperature (19^25‡C). Single
channel currents were ¢ltered at 70 Hz low pass and changes in KATP
channel open state probability were estimated ‘o¡-line’ by analysis of
25^30 s stretches of continuous data using a CED 1401 interface and
designated software (Cambridge Electronic Design, Cambridge, UK)
as described previously [38].
Average concentration/response data are expressed as a percentage
of the initial control value and plotted using Excel (Microsoft Cor-
poration, USA) as mean values þ S.E.M. Unpaired Student’s t-tests
were carried out to determine the signi¢cance of di¡erences in the
KATP channel activity at equivalent concentrations of efaroxan and
KU08C. All current traces are displayed as upward de£ections, which
represent outward current events.
2.3. Insulin secretion studies
Isolated human pancreatic islets were provided by Drs. R.F.L.
James, S. Swift and H. Clayton (Dept. of Surgery, University of
Leicester) and were incubated in groups of 3 in 0.5 ml of incubation
medium as described previously [40]. Following incubation at 37‡C
with appropriate test reagents, samples of the medium were removed
and assayed for insulin by a radioimmunoassay. Crystalline biosyn-
thetic human insulin was used as a standard.
3. Results and discussion
3.1. The E¡ect of KU08C on insulin secretion
The imidazoline derivative efaroxan is a potent antagonist
at imidazoline I1 sites [36] whereas it shows a signi¢cant ago-
nist activity at the putative imidazoline I3 sites expressed in
pancreatic L-cells [4,19,20,22]. Thus it seems likely that deriv-
atives of efaroxan will be useful reagents for a⁄nity puri¢ca-
tion of these, still elusive, imidazoline receptor classes. In the
present work, we have coupled efaroxan to an a⁄nity resin
via an amino group substituted at position ¢ve of the parent
molecule to generate the derivative KU08C [37]. KU08C was
previously shown to retain the ability of efaroxan to stimulate
insulin secretion from isolated rat islets, albeit with a slightly
reduced potency [37]. We now demonstrate that KU08C is
also agonistic in human islets (Fig. 1) since it was able to
dose-dependently reverse the inhibition of glucose-induced in-
sulin secretion mediated by the KATP channel agonist diazo-
xide. This e¡ect is characteristic of imidazoline insulin secre-
tagogues and the results are consistent with the possibility
that KU08C is able to regulate the opening of KATP channels
in human pancreatic L-cells.
3.2. Patch clamp analysis of the e¡ects of KU08C on human
pancreatic L-cell KATP channels
In order to con¢rm that KU08C is able to inhibit KATP
channels in human pancreatic L-cells, electrophysiological re-
cordings were performed on isolated, cultured human L-cells.
These were derived from the same preparations of islets used
in the insulin secretion studies described above, to allow direct
comparison of the data. A total of 22 recordings were made
using cell-free inside-out membrane patches. Under the exper-
imental conditions described, KATP channels were spontane-
ously active and could be reversibly inhibited by ATP
(0.5 mM) applied to the inside of the patch of the membrane.
Direct application of either efaroxan (0.1 mM) or KU08C (0.1
mM) produced a reversible inhibition of channel activity in
n = 8/8 and n = 5/5 patches, respectively. To minimise run
down of KATP channels, inside-out patches were exposed to
0.5 mM ATP unless the actions of efaroxan or KU08C were
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Fig. 1. Stimulation of insulin secretion from isolated human islets
by KU08C. Groups of three isolated human pancreatic islets were
incubated with 20 mM glucose and 200 WM diazoxide and then in-
creasing concentrations of KU08C, as shown. Following incubation
for 1 h at 37‡C, samples of the medium were removed and assayed
for insulin content by a radioimmunoassay. Each point represents
the mean rate of insulin secretion þ S.E.M. for six observations.
Similar results were obtained with two separate batches of islets.
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studied (Fig. 2A). Under these conditions, concentration/re-
sponse (0.001^0.1 mM) pro¢les were generated for both efar-
oxan (n = 9) and KU08C (n = 7). Analysis of these data (n = 7,
Fig. 2B) indicated that in human islet cells, the approximate
half maximal blocking concentrations were 1 WM for efaroxan
and 25 WM for KU08C. Thus, these electrophysiological stud-
ies con¢rm that the mode of action of KU08C involves in-
hibition of KATP channels in L-cells. Overall, KU08C is some-
what less potent than equivalent concentrations of efaroxan,
but nevertheless the compound is a signi¢cant modulator of L-
cell KATP channels.
3.3. A⁄nity chromatography with KU08C
Pancreatic islets are available in only relatively small quan-
tities and are unlikely to serve as a useful source of protein for
a⁄nity puri¢cation purposes unless the target is expressed at
very high levels. By contrast, rat brain is an abundant source
of tissue and it expresses both I1- and I2-imidazoline binding
sites, as well as KATP channels. Thus, it represents an approp-
riate source of starting material for a⁄nity puri¢cation of
imidazoline binding proteins.
Previous work has shown that KU08C possesses a negli-
gible a⁄nity for I2 sites and is only weakly potent as an K2-
adrenoceptor ligand [41]. Thus, a⁄nity resins based on
KU08C are unlikely to speci¢cally retain either of these types
of receptor. However, it is possible that both I1- and I3-imid-
azoline binding sites could be retained. When solubilised
extracts of rat brain were applied to an a⁄nity column de-
rived from KU08C, a number of proteins were retained which
could then be eluted on subsequent application of imidazoline
reagents or high salt concentrations (Fig. 3A). A major species
with an approximate molecular weight of 60 kDa was de-
tected in all eluates and silver staining of SDS-PAGE gels
revealed a range of additional proteins (30 kDa^70 kDa).
None of these proteins was immunoreactive with an anti-I2-
imidazoline receptor serum (kindly provided by Dr D. Reis,
Cornell University Medical School) nor with an anti-K2-adre-
noceptor antibody (from Santa-Cruz) consistent with the ex-
pectation that such molecules would not be readily retained
on the resin. However, Western blotting of eluted proteins
with an antiserum raised against the pore forming subunit
of L-cell KATP channels, Kir6.2 (kindly provided by Prof. S.
Seino, Chiba University, Japan) revealed a single immuno-
reactive species (molecular weight V50 kDa) which could
be eluted from the column by efaroxan (Fig. 3B).
These results suggest that efaroxan can interact with Kir6.2
or with a closely related member of the Kir6.x family in rat
brain extracts. We suggest that this is likely to be Kir6.2 itself
since the antibody used to detect the protein was raised
against the C-terminal sequence of Kir6.2 (S. Seino, personal
communication) and this region represents that over which
Kir6.2 and Kir6.1 are most divergent. Moreover, the ¢nding
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Fig. 3. Retention of proteins present in extracts of rat brain on a
KU08C a⁄nity column. Solubilised extracts of rat brain were ap-
plied to an a⁄nity matrix containing KU08C and, after extensive
washing, retained proteins were eluted with UK14304 (1 mM, lane
1) efaroxan (100 WM, lane 2) or KCl (1 M, lane 3). Eluted proteins
were dialysed and concentrated prior to electrophoresis on SDS
gels. A shows the protein pro¢le of each eluate after silver staining
of the gel. B shows a Western blot of each eluate probed with a
polyclonal antiserum raised against Kir6.2 (diluted 1:2000) after
transfer to a PVDF membrane. Immunoreactive bands were de-
tected colorimetrically using a secondary antibody coupled to alka-
line phosphatase. Similar results were obtained with three di¡erent
brain preparations.
Fig. 2. E¡ects of KU08C and efaroxan on ATP-sensitive potassium channel activity in isolated human pancreatic L-cells. The opening of hu-
man L-cell KATP channels was monitored by patch clamp recording in the presence and absence of 0.5 mM ATP and increasing concentrations
of either KU08C (A, upper trace) or efaroxan (A, lower trace). The summated results from a number of experiments is shown in B which al-
lows a comparison of the dose-response relationship for channel closure by each drug. The level of channel opening in the absence of drug
(Po) is given as 100%. *P6 0.05; **P6 0.01 versus absence of KU08C.
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that KU08C exhibits a signi¢cant functional activity in pan-
creatic L-cells supports the involvement of Kir6.2 as a site of
action, since Kir6.2 forms the ion conducting pore component
of L-cell KATP channels.
Despite the considerations above, it should be emphasised
that the data do not formally exclude the possibility that the
imidazoline binding site controlling KATP channels may reside
on a separate protein which is tightly associated with Kir6.2 in
the brain, rather than with Kir6.2 itself. In either case, the
present data o¡er the ¢rst direct biochemical evidence that
components of the KATP channel can represent important
targets for imidazoline molecules.
Acknowledgements: Financial support from the Wellcome Trust
(LKM, NGM, SLFC) and British Diabetic Association (NGM,
CAR, MJD) is gratefully acknowledged. KE Cosgrove was supported
by an MRC research studentship. We also thank Drs Roger James,
Sue Swift and Heather Clayton for the provision of human islets and
Prof. S. Seino for a gift of the anti-Kir6.2 serum.
References
[1] Bousquet, P. (1995) J. Cardiovasc. Pharmacol. 26, S1^S6.
[2] Molderings, G.J. (1997) Drugs Future 22, 757^772.
[3] Parini, A., Moudanos, C.G., Pizzinat, N. and Lanier, S.M.
(1996) Trends Pharmacol. Sci. 17, 13^16.
[4] Eglen, R.M., Hudson, A.L., Kendall, D.A., Nutt, D.J., Morgan,
N.G., Wilson, V.G. and Dillon, M.P. (1998) Trends Pharmacol.
Sci. 19, 381^390.
[5] French, N. (1995) Pharmacol. Ther. 68, 175^208.
[6] Escriba, P.V., Ozaita, A., Miralles, A., Reis, D.J. and Garcia-
Sevilla, J.A. (1995) Mol. Brain Res. 32, 187^196.
[7] Greney, H., Bennai, F., Molines, A., Belcourt, A., Dontenwill,
M. and Bousquet, P. (1994) Eur. J. Pharmacol. 265, R1^R2.
[8] Lione, L.A., Nutt, D.J. and Hudson, A.L. (1998) Eur. J. Phar-
macol. 353, 123^135.
[9] Ernsberger, P.R., Graves, M.E., Gra¡, L.M., Zakieh, N., Nguy-
en, P., Collins, L.A., Westbrooks, K.L. and Johnson, G.G.
(1995) Ann. New York Acad. Sci. 763, 22^42.
[10] Ugedo, L., Pineda, J., Ruiz-Ortega, J.A. and Martin-Ruiz, R.
(1998) Br. J. Pharmacol. 125, 1685^1694.
[11] Gothert, M. and Molderings, G.J. (1991) Naunyn-Schmiede-
berg’s Arch. Pharmacol. 343, 271^282.
[12] Coupry, I., Podevin, R.A., Dausse, J.P. and Parini, A. (1987)
Biochem. Biophys. Res. Commun. 147, 1055^1060.
[13] Evans, R.G. and Haynes, J.M. (1994) Clin. Exp. Pharmacol.
Physiol. 21, 649^658.
[14] Allan, D.R., Penner, S.B. and Smyth, D.D. (1993) Br. J. Phar-
macol. 108, 875.
[15] Head, G.A. (1995) Ann. New York Acad. Sci. 763, 531^540.
[16] Piletz, J.E., Andorn, A.C., Unnerstall, J.R. and Halaris, A.
(1991) Biochem. Pharmacol. 42, 569^584.
[17] Diamant, S., Eldar-Geva, T. and Atlas, D. (1992) Br. J. Pharma-
col. 106, 101^108.
[18] Schulz, A. and Hasselblatt, A. (1988) Naunyn-Schmiedeberg’s
Arch. Pharmacol. 337, 637^643.
[19] Chan, S.L.F. and Morgan, N.G. (1990) Eur. J. Pharmacol. 176,
97^101.
[20] Berdeu, D., Gross, R., Ribes, G., Loubatieres-Mariani, M.-M.
and Bertrand, G. (1994) Eur. J. Pharmacol. 254, 119^125.
[21] Rustenbeck, I., Kopp, M., Polzin, C. and Hasselblatt, A. (1998)
Naunyn-Schmiedeberg’s Arch. Pharmacol. 358, 390^393.
[22] Mourtada, M., Smith, S.A. and Morgan, N.G. (1998) Eur.
J. Pharmacol. 350, 251^258.
[23] Dunne, M.J. (1991) Br. J. Pharmacol. 103, 1847^1850.
[24] Plant, T.D., Jonas, J.-C. and Henquin, J.-C. (1991) Br. J. Phar-
macol. 104, 385^390.
[25] Jonas, J.-C., Plant, T.D. and Henquin, J.-C. (1992) Br. J. Phar-
macol. 107, 8^14.
[26] Proks, P. and Ashcroft, F.M. (1997) Proc. Natl. Acad. Sci. USA
94, 11716^11720.
[27] Dunne, M.J., Harding, E., Jagger, J., Squires, P., Liang, R.,
Kane, C., London, N.J.M. and James, R.F.L. (1995) Ann.
New York Acad. Sci. 763, 243^262.
[28] Morgan, N.G., Chan, S.L.F., Mourtada, M., Monks, L.M. and
Ramsden, C.A. (1999) Ann. N.Y. Acad. Sci. (in press).
[29] Babenko, A.P., Aguilar-Bryan, L. and Bryan, J. (1998) Ann.
Rev. Physiol. 60, 667^687.
[30] Clement, J.P., Kunjilwar, K., Gonzalez, G., Schwanstecher, M.,
Panten, U., Aguilar-Bryan, L. and Bryan, J. (1997) Neuron 18,
827^838.
[31] Aguilar-Bryan, L., Clement, J.P., Gonzalez, G., Kunjilwar, K.,
Babenko, A. and Bryan, J. (1998) Physiol. Rev. 78, 227^245.
[32] Ashcroft, F.M. and Gribble, F.M. (1998) Trends Neurosci. 21,
288^294.
[33] Inagaki, N., Tsuura, Y., Namba, N., Masuda, K., Gonoi, T.,
Horie, M., Seino, Y., Mizuta, M. and Seino, S. (1995) J. Biol.
Chem. 270, 5691^5694.
[34] Inagaki, N., Gonoi, T., Clement, J.P., Namba, N., Inazawa, J.,
Gonzalez, G., Aguilar-Bryan, L., Seino, S. and Bryan, J. (1995)
Science 270, 1166^1170.
[35] Brown, C.A., Chan, S.L.F., Stillings, M.R., Smith, S.A. and
Morgan, N.G. (1993) Br. J. Pharmacol. 110, 1017^1022.
[36] Ernsberger, P., Graves, M.E., Gra¡, L.M., Zakieh, N., Nguyen,
P., Collins, L.A., Westbrooks, K.L. and Johnson, G.D. (1995)
Ann. New York Acad. Sci. 763, 22^42.
[37] Chan, S.L.F., Pallet, A.L., Clews, J., Ramsden, C.A., Chapman,
J.C., Kane, C., Dunne, M.J. and Morgan, N.G. (1998) Eur.
J. Pharmacol. 355, 67^76.
[38] Dunne, M.J., Illot, M.C. and Peterson, O.H. (1987) J. Membr.
Biol. 99, 215^224.
[39] Findlay, I. and Dunne, M.J. (1986) P£ug. Arch. 407, 238^240.
[40] Lacey, R.J., Cable, H.C., James, R.F., London, N.J.M., Scarpel-
lo, J.H.B. and Morgan, N.G. (1993) J. Endocrinol. 138, 555^563.
[41] Tyacke, R.J., Nutt, D.J., Chan, S.L.F., Ramsden, C.A., Morgan,
N.G. and Hudson, A.L. (1997) Br. J. Pharmacol. 122, SS66.
FEBS 21732 18-3-99
L.K. Monks et al./FEBS Letters 447 (1999) 61^6464
